A journal of IEEE and CAA , publishes high-quality papers in English on original theoretical/experimental research and development in all areas of automation
Volume 13 Issue 10
Oct.  2026

IEEE/CAA Journal of Automatica Sinica

  • JCR Impact Factor: 18.3, Top 1 (SCI Q1)
    CiteScore: 28.2, Top 1% (Q1)
    Google Scholar h5-index: 95, TOP 5
Turn off MathJax
Article Contents
W. Li, “A causal learning-based virtual population framework for chronic disease analysis,” IEEE/CAA J. Autom. Sinica, vol. 13, no. 10, pp. 2210–2221, Oct. 2026. doi: 10.1109/JAS.2026.126455
Citation: W. Li, “A causal learning-based virtual population framework for chronic disease analysis,” IEEE/CAA J. Autom. Sinica, vol. 13, no. 10, pp. 2210–2221, Oct. 2026. doi: 10.1109/JAS.2026.126455

A Causal Learning-Based Virtual Population Framework for Chronic Disease Analysis

doi: 10.1109/JAS.2026.126455
Funds:  This work was supported by Taishan Scholars Program for Young Experts (tsqn202507081)
More Information
  • Causal analysis is essential for precise chronic disease management. Chronic diseases are characterized by complex risk-factor interactions, substantial patient heterogeneity, and frequent missingness and measurement uncertainty in real-world medical data. Existing heterogeneity analyses are still largely phenotype-driven, whereas most machine learning methods are correlation-based and lack interpretable mechanism modeling. As a result, mechanism-aware patient stratification remains insufficiently addressed. Methodologically, to uncover more comprehensive causal mechanisms, a causal learning-based virtual population modeling framework is proposed for chronic disease heterogeneity analysis. A biomedical causal prior graph over risk factors is first incorporated to construct patient-level virtual phenotypic profiles, by which each patient is represented relative to a clinically meaningful causal reference. To improve robustness to incomplete and noisy electronic health record data, medically plausible perturbed views are generated through feature masking, random dropout, and mild observation perturbation, and stable patient representations are further learned by contrastive refinement. On this basis, a virtual population is formed in the learned phenotypic space for hidden subgroup discovery. To characterize disease heterogeneity mechanistically, subgroup-specific disease mechanisms are modeled as deviations from a standard pattern, so that common pathophysiological regularities and subgroup-dependent variations can be jointly captured. In the hypertension case study, a new heterogeneity model and novel subtypes are identified, and prognostic relevance, biomarker predictive value, distinct mechanistic patterns, and potential intervention implications are demonstrated. These results suggest that causal virtual population modeling can provide a useful framework for precision chronic disease analysis.

     

  • loading
  • [1]
    P. Sanchez, J. P. Voisey, T. Xia, H. I. Watson, A. Q. O’Neil, and S. A. Tsaftaris, “Causal machine learning for healthcare and precision medicine,” R. Soc. Open Sci., vol. 9, no. 8, Art. no. 220638, Aug. 2022. doi: 10.1098/rsos.220638
    [2]
    L. Xu, “An overview and perspectives on bidirectional intelligence: Lmser duality, double IA harmony, and causal computation,” IEEE/CAA J. Autom. Sinica, vol. 6, no. 4, pp. 865−893, Jul. 2019. doi: 10.1109/jas.2019.1911603
    [3]
    I. Bica, A. M. Alaa, C. Lambert, and M. van der Schaar, “From real-world patient data to individualized treatment effects using machine learning: Current and future methods to address underlying challenges,” Clin. Pharmacol. Ther., vol. 109, no. 1, pp. 87−100, Jan. 2021. doi: 10.1002/cpt.1907
    [4]
    D. K. Tobias, J. Merino, A. Ahmad, C. Aiken, J. L. Benham, D. Bodhini, A. L. Clark, K. Colclough, R.Corcoy, S. J. Cromer, et al., “Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine,” Nat. Med., vol. 29, no. 10, pp. 2438−2457, Oct. 2023. doi: 10.1038/s41591-023-02502-5
    [5]
    M. Prosperi, Y. Guo, M. Sperrin, J. S. Koopman, J. S. Min, X. He, S. Rich, M. Wang, I. E. Buchan, and J. Bian, “Causal inference and counterfactual prediction in machine learning for actionable healthcare,” Nat. Mach. Intell., vol. 2, no. 7, pp. 369−375, Jul. 2020. doi: 10.1038/s42256-020-0197-y
    [6]
    D. C. Whitcomb, “Primer on precision medicine for complex chronic disorders,” Clin. Transl. Gastroenterol., vol. 10, no. 7, Art. no. e00067, Jul. 2019. doi: 10.14309/ctg.0000000000000067
    [7]
    R. C. Wang and Z. Wang, “Precision medicine: Disease subtyping and tailored treatment,” Cancers, vol. 15, no. 15, Art. no. 3837, Jul. 2023. doi: 10.3390/cancers15153837
    [8]
    O. A. Carretero and S. Oparil, “Essential hypertension: Part I: Definition and etiology,” Circulation, vol. 101, no. 3, pp. 329−335, Jan. 2000. doi: 10.1161/01.CIR.101.3.329
    [9]
    D. G. Harrison, T. M. Coffman, and C. S. Wilcox, “Pathophysiology of hypertension: The mosaic theory and beyond,” Circ. Res., vol. 128, no. 7, pp. 847−863, Apr. 2021. doi: 10.1161/CIRCRESAHA.121.318082
    [10]
    J. Sundström, L. Lind, S. Nowrouzi, E. Hagström, C. Held, P. Lytsy, B. Neal, K. Marttala, and O. Östlund, “Heterogeneity in blood pressure response to 4 antihypertensive drugs: A randomized clinical trial,” JAMA, vol. 329, no. 14, pp. 1160−1169, Apr. 2023. doi: 10.1001/jama.2023.3322
    [11]
    S. Padmanabhan and A. F. Dominiczak, “Genomics of hypertension: The road to precision medicine,” Nat. Rev. Cardiol., vol. 18, no. 4, pp. 235−250, Apr. 2021. doi: 10.1038/s41569-020-00466-4
    [12]
    G. Parati, C. Lombardi, M. Pengo, G. Bilo, and J. E. Ochoa, “Current challenges for hypertension management: From better hypertension diagnosis to improved patients’ adherence and blood pressure control,” Int. J. Cardiol., vol. 331, pp. 262−269, May 2021. doi: 10.1016/j.ijcard.2021.01.070
    [13]
    T. J. Guzik, R. Nosalski, P. Maffia, and G. R. Drummond, “Immune and inflammatory mechanisms in hypertension,” Nat. Rev. Cardiol., vol. 21, no. 6, pp. 396−416, Jun. 2024. doi: 10.1038/s41569-023-00964-1
    [14]
    J. W. McEvoy, C. P. McCarthy, R. M. Bruno, S. Brouwers, M. D. Canavan, C. Ceconi, R. M. Christodorescu, S. S. Daskalopoulou, C. J. Ferro, E. Gerdts, et al., “2024 ESC guidelines for the management of elevated blood pressure and hypertension,” Eur. Heart J., vol. 45, no. 38, pp. 3912−4018, Oct. 2024. doi: 10.1093/eurheartj/ehae178
    [15]
    D. W. Jones, K. C. Ferdinand, S. J. Taler, H. M. Johnson, D. Shimbo, M. Abdalla, M. M. Altieri, N. Bansal, N. A. Bello, A. P. Bress, et al., “2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines,” Hypertension, vol. 82, no. 10, pp. e212−e316, Oct. 2025.
    [16]
    V. J. Dzau and C. P. Hodgkinson, “Precision hypertension,” Hypertension, vol. 81, no. 4, pp. 702−708, Apr. 2024. doi: 10.1161/HYPERTENSIONAHA.123.21710
    [17]
    S. Imran, T. Mahmood, A. Morshed, and T. Sellis, “Big data analytics in healthcare – A systematic literature review and roadmap for practical implementation,” IEEE/CAA J. Autom. Sinica, vol. 8, no. 1, pp. 1−22, Jan. 2021. doi: 10.1109/jas.2020.1003384
    [18]
    M. A. Gianfrancesco and N. D. Goldstein, “A narrative review on the validity of electronic health record-based research in epidemiology,” BMC Med. Res. Methodol., vol. 21, no. 1, Art. no. 234, Oct. 2021. doi: 10.1186/s12874-021-01416-5
    [19]
    B. Glocker, M. Musolesi, J. Richens, and C. Uhler, “Causality in digital medicine,” Nat. Commun., vol. 12, no. 1, Art. no. 5471, Sep. 2021.
    [20]
    K. Jiang, W. Liu, Y. Wang, L. Dong, and C. Sun, “Discovering latent variables for the tasks with confounders in multi-agent reinforcement learning,” IEEE/CAA J. Autom. Sinica, vol. 11, no. 7, pp. 1591−1604, Jul. 2024. doi: 10.1109/JAS.2024.124281
    [21]
    D. C. Aron, “Precision medicine and the challenges of human complexity,” Psychother. Psychosom., vol. 92, no. 6, pp. 349−353, Nov. 2023.
    [22]
    Å. Johansson, O. A. Andreassen, S. Brunak, P. W. Franks, H. Hedman, R. J. F. Loos, B. Meder, E. Melén, C. E. Wheelock, and B. Jacobsson, “Precision medicine in complex diseases-Molecular subgrouping for improved prediction and treatment stratification,” J. Intern. Med., vol. 294, no. 4, pp. 378−396, Oct. 2023. doi: 10.1111/joim.13640
    [23]
    A. Chaddad, Q. Lu, J. Li, Y. Katib, R. Kateb, C. Tanougast, A. Bouridane, and A. Abdulkadir, “Explainable, domain-adaptive, and federated artificial intelligence in medicine,” IEEE/CAA J. Autom. Sinica, vol. 10, no. 4, pp. 859−876, Apr. 2023. doi: 10.1109/JAS.2023.123123
    [24]
    S.-C. Lu, C. L. Swisher, C. Chung, D. Jaffray, and C. Sidey-Gibbons, “On the importance of interpretable machine learning predictions to inform clinical decision making in oncology,” Front. Oncol., vol. 13, Art. no. 1129380, Feb. 2023. doi: 10.3389/fonc.2023.1129380
    [25]
    A. S. Tang, S. R. Woldemariam, S. Miramontes, B. Norgeot, T. T. Oskotsky, and M. Sirota, “Harnessing EHR data for health research,” Nat. Med., vol. 30, no. 7, pp. 1847−1855, Jul. 2024. doi: 10.1038/s41591-024-03074-8
    [26]
    S. Zhou, Z. Xu, M. Zhang, C. Xu, Y. Guo, Z. Zhan, Y. Fang, S. Ding, J. Wang, K. Xu, et al., “Large language models for disease diagnosis: A scoping review,” NPJ Artif. Intell., vol. 1, no. 1, Art. no. 9, Jun. 2025. doi: 10.1038/s44387-025-00011-z
    [27]
    A. A. Armoundas, S. M. Narayan, D. K. Arnett, K. Spector-Bagdady, D. A. Bennett, L. A. Celi, et al., “Use of artificial intelligence in improving outcomes in heart disease: A scientific statement from the American Heart Association,” Circulation, vol. 149, no. 14, pp. e1028−e1050, Apr. 2024.
    [28]
    J. Abécassis, É. Dumas, J. Alberge, and G. Varoquaux, “From prediction to prescription: Machine learning and causal inference for the heterogeneous treatment effect,” Annu. Rev. Biomed. Data Sci., vol. 8, pp. 381−404, Aug. 2025. doi: 10.1146/annurev-biodatasci-103123-095750
    [29]
    S. Brouwers, I. Sudano, Y. Kokubo, and E. M. Sulaica, “Arterial hypertension,” Lancet, vol. 398, no. 10296, pp. 249−261, Jul. 2021. doi: 10.1016/S0140-6736(21)00221-X
    [30]
    R. J. Boffa, M. Constanti, C. N. Floyd, and A. S. Wierzbicki, “Hypertension in adults: Summary of updated NICE guidance,” BMJ, vol. 367, Art. no. l5310, Oct. 2019. doi: 10.1136/bmj.l5310
    [31]
    R. M. Touyz and E. L. Schiffrin, “A compendium on hypertension: New advances and future impact,” Circ. Res., vol. 128, no. 7, pp. 803−807, Apr. 2021. doi: 10.1161/CIRCRESAHA.121.319181
    [32]
    Z. Sun, W. Dong, J. Shi, and Z. Huang, “Interpretable disease progression prediction based on reinforcement reasoning over a knowledge graph,” IEEE Trans. Syst., Man, Cybern. Syst., vol. 54, no. 3, pp. 1948−1959, Mar. 2024. doi: 10.1109/TSMC.2023.3331847
    [33]
    J. Ge, Y. Xu, and C. Wang, Internal Medicine. 9th ed. Beijing, China: People’s Medical Publishing House, 2018.
    [34]
    A. E. W. Johnson, T. J. Pollard, L. Shen, L.-W. H. Lehman, M. Feng, M. Ghassemi, B. Moody, P. Szolovits, L. A. Celi, and R. G. Mark, “MIMIC-III, a freely accessible critical care database,” Sci. Data, vol. 3, Art. no. 160035, May 2016. doi: 10.1038/sdata.2016.35
    [35]
    L. McInnes, J. Healy, and J. Melville, “UMAP: Uniform manifold approximation and projection for dimension reduction,” arXiv preprint arXiv: 1802.03426, 2018.
    [36]
    S. Hong, H. He, P. Fang, S. Liu, and C. Chen, “Association of neutrophil-to-lymphocyte ratio and risk of cardiovascular and all-cause mortality in hypertension patients,” Heliyon, vol. 10, no. 6, Art. no. e27517, Mar. 2024. doi: 10.1016/j.heliyon.2024.e27517
    [37]
    R. Xue, Q. Zhang, Q. Cao, R. Kong, X. Xiang, H. Liu, M. Feng, F. Wang, J. Cheng, Z. Li, et al., “Liver tumour immune microenvironment subtypes and neutrophil heterogeneity,” Nature, vol. 612, no. 7938, pp. 141−147, Dec. 2022. doi: 10.1038/s41586-022-05400-x
    [38]
    W. Li, W. Zhang, Q. Zhang, X. Zhang, and X. Wang, “Weakly supervised causal discovery based on fuzzy knowledge and complex data complementarity,” IEEE Trans. Fuzzy Syst., vol. 32, no. 12, pp. 7002−7014, Dec. 2024. doi: 10.1109/TFUZZ.2024.3471187
    [39]
    W. Li, Q. Zhang, and X. Wang, “Mechanisms under shifts: Interpretable clustering with self-improving heterogeneous causal graphs,” IEEE Trans. Pattern Anal. Mach. Intell., vol. 48, no. 8, pp. 10083−10096, Aug. 2026. doi: 10.1109/TPAMI.2026.3683072

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(2)

    Article Metrics

    Article views (15) PDF downloads(2) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return